By Biomedtracker 08 Feb 2017
In this report, we cover catalysts from 36 drugs, devices and diagnostics expected to occur in early 2017.
Keep your finger on the pulse of upcoming major marked events and let Biomedtracker guide you in understanding how it impacts the market and drug development landscape as soon as it happens.
How it works
We track impactful future catalysts, analyze these commercial, clinical and regulatory activities when they happen and present them in an easily searchable interface to help you stay on top of your game. And, our analysts attend medical and investor meetings that matter to you, to bring not just the the news, but our industry-acclaimed insight to you faster.
How it can help
Biomedtracker's team of expert analysts monitors the companies, trials, deals and regulatory meetings to capture the most critical events so that you can spend more time making the right decisions for your buisness. Our Likelihood of Approval analyses are informed by these events and showcase the "bottom-line" of the news' impact on a drug's future.
Biomedtracker uniquely tracks and analyzes every event in the drug development world in real-time and sends custom email alerts based on your preferences.
Access all of the data you need to monitor the market in one place – drugs, companies, indications, targets, catalysts, endpoint data, trials, and more.
Our medical and investor conference planners and post-reports keep you abreast of developments from major meetings like JP Morgan, ASCO, and EASL.
Predict how future FDA panels may vote before the meeting happens. AdComm Insight lets subscribers see the voting history of the FDA panelists who will be adjudicating the approvability of an upcoming drug.
Your subscription to Biomedtracker includes direct access to our analyst team.
By Matt Dias 27 Apr 2016
Summary The 34th annual JP Morgan Healthcare Conference was held in San Francisco, CA from January 11-14, 2016. A comprehensive list of events and catalysts that were announced or updated at the conference is included in this report. Additionally, below are some key points from the conference’s company presentations.
By Clara Tan 16 Sep 2015
The enactment of the US FDA Biosimilar 351(k) pathway in March 2010 has created uncertainty on many fronts. The innovator, biosimilar developer, FDA, and payer have spent years readjusting their strategies to prepare for the introduction of biosimilars in the US.
By Justin Burns 11 Sep 2015
In August, Forbes’ reporter Matthew Herper penned an article using data from the BioMedTracker database highlighting the unprecedented rate of approval by the U.S. Food & Drug Administration (FDA) for new molecular entity (NME) applications in recent years.
By Julie McKenna 29 Jan 2015
The annual J.P. Morgan Healthcare Conference wrapped up earlier this month in San Francisco with a huge gathering of biotech and pharma companies coming together to discuss pipelines, partnerships, and promises for the new year.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: